The Nasdaq’s win streak, Netflix earnings, another AI pivot and more in Morning Squawk

Stocks climbed higher in yesterday’s session after President Donald Trump announced that Israel and Lebanon agreed to 10-day ceasefire, inviting leaders from both countries to the White House for peace talks. Iran had previous called Israeli attacks on Lebanon a violation of Tehran’s own ceasefire with the U.S.

Here’s what to know:

Netflix beat analyst expectations for revenue in the first quarter yesterday. The streaming giant saw a big jump in earnings per share thanks partly to the $2.8 billion breakup fee it received following the termination of its proposed Warner Bros. Discovery deal.

The California-based company also announced a key leadership change: Chairman, co-founder and former CEO Reed Hastings will step down from Netflix’s board after his term ends in June. Co-CEO Ted Sarandos wrote off the idea that Hastings’ departure is tied to the WBD deal, calling Hastings a “big champion” for Netflix’s bid for WBD’s assets.

Netflix shares tumbled around 10% in premarket trading.

Quantum stocks have surged this week amid investor optimism that Nvidia‘s open-source artificial intelligence models will boost quantum computing adoption. IonQ and D-Wave Quantum shares have soared more than 50% just this week, while Quantum Computing and Rigetti Computing have climbed more than 30%.

At the same time, shares of Taiwan Semiconductor and ASML sank despite strong earnings reports from both chip manufacturers. As CNBC’s Katie Tarasov reports, their moves are the latest example of chipmaker stocks buckling under the weight of lofty expectations.

Allbirds isn’t the only company unexpectedly pivoting to AI this week: Social media company Myseum announced that it is zeroing in on using AI agents for personalization on its platforms.

Shares of the penny stock jumped about 130% in Thursday’s session. While the company is changing its name to Myseum.AI, it said it will continue to trade under the MYSE ticker.

The move comes after retail investors rushed into Allbirds’ stock following its own announcement that it would shift its focus from shoes to AI. But as CNBC’s Yun Li notes, history shows that this type of trade doesn’t typically pan out well.

Health and Human Services Secretary Robert F. Kennedy Jr. signaled this week that regulators could ease restrictions on peptides. That could be welcome news for Hims & Hers as it looks for its next growth driver after GLP-1s.

As CNBC’s Brandon Gomez reports, the telehealth company has been working on its peptide business for years, notably acquiring a California-based peptide facility in 2025. Peptides are controversial: Their production is largely unregulated and there’s limited scientific data on the long-term safety or efficacy of their use.